CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 26, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance
of patents covering its novel Toll-like Receptor (TLR) - targeted
compounds. The Company’s TLR-targeted compounds are based on synthetic
DNA and RNA, which it refers to as immune modulatory oligonucleotides,
or IMO®. Idera’s intellectual property portfolio contains
over 500 patents and patent applications worldwide, which includes
claims for TLR-targeted compounds, second-generation antisense
chemistry, and oral delivery of certain oligonucleotides.
“The claims of these issued patents cover Idera’s IMO compositions, the
use of IMOs in treating and preventing diseases, and the combination of
IMOs with certain monoclonal antibodies for the treatment of cancer,”
commented Steve Ritter, Ph.D., J.D., Vice President of Intellectual
Property and Contracts. “These patents expand the patent protection for
TLR-targeted compounds in our pipeline.”
The recently issued patents include:
-
US 7,595,305, entitled “Modulation Of Immunostimulatory Properties Of
Oligonucleotide-Based Compounds By Utilizing Modified
Immunostimulatory Dinucleotides”
-
US 7,569,554, entitled “Synergistic Treatment of Cancer Using
Immunomers in Conjunction with Chemotherapeutic Agents”
-
US 7,566,702, entitled “Immunostimulatory Oligonucletide Multimers”
In addition to the issued U.S. patents, patents corresponding to the US
7,569,554 patent were granted to the Company in Guatemala, Latvia,
Macedonia, Morocco, New Zealand, and Singapore. The Company was also
granted patents entitled “Synergistic Stimulation of the Immune System
Using Immunostimulatory Oligonucleotides and/ or Immunomer Compounds in
Conjunction with Cytokines and/or Chemotherapeutic Agents or Radiation
Therapy” in China (ZL200480026430.5) and India (228,424).
About Idera’s Intellectual Property Portfolio
Idera’s intellectual property portfolio contains over 500 patents and
patent applications worldwide.
Immune Modulatory Oligonucleotides (IMO®)
This portfolio holds over 280 patents and patent applications worldwide
covering Idera’s IMO technologies, which includes claims covering novel
agonists of Toll-like Receptors (TLRs) 7, 8 and 9 and antagonists of
TLRs 7 and 9. These patents and patent applications include claims
covering IMO-2055, IMO-2125, IMO-3100, and QAX935.
Antisense Technology
This portfolio holds over 220 patents and patent applications worldwide
covering novel antisense compounds and methods of their use. These
patents and patent applications include claims covering
second-generation antisense chemistry, oral delivery of
second-generation antisense compounds, and certain genes, antisense
sequences, and therapeutic targets (including various TLRs and signaling
molecules).
As of October 2009, the Company has been recognized four times over the
past two years by the Patent Board™ as one of the top 35 companies in
the biotechnology field based on its technology and intellectual
property advances. The Patent Board™ is an independent group that tracks
and analyzes intellectual property and technology assets across 17
industries globally and publishes its results in the Wall Street
Journal.
Please visit http://www.iderapharma.com/science/intellectual_property.php
for more information about Idera’s intellectual property portfolio.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious
diseases, autoimmune and inflammatory diseases, cancer, and respiratory
diseases, and for use as vaccine adjuvants. Our proprietary drug
candidates are designed to modulate specific Toll-like Receptors, which
are a family of immune system receptors that direct immune system
responses. Our pioneering DNA and RNA chemistry expertise enables us to
create drug candidates for internal development and generates
opportunities for multiple collaborative alliances. For more
information, visit www.iderapharma.com.
Idera Forward Looking Statements
This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc., which involve a number of risks and
uncertainties. For this purpose, any statements contained herein that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the words
"believes," "anticipates," "plans," "expects," "estimates," "intends,"
"should," "could," "will," "may," and similar expressions are intended
to identify forward-looking statements. There are a number of important
factors that could cause the Company’s actual results to differ
materially from those indicated by such forward-looking statements,
including whether products based on the Company’s technology will
advance into or through the clinical trial process on a timely basis or
at all and receive approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; whether, if
the Company's products receive approval, they will be successfully
distributed and marketed; whether the Company’s collaborators will
support the development and commercialization of products under their
collaborations with the Company; whether the patents and patent
applications owned or licensed by the Company such as the patents and
patent applications referenced above will protect the Company’s
technology and prevent others from infringing it; whether the Company’s
cash resources will be sufficient to fund the Company's operations; and
such other important factors as are set forth under the caption "Risk
Factors" in the Company’s Quarterly Report on Form 10-Q for the three
months ended June 30, 2009, which important factors are incorporated
herein by reference. The Company disclaims any intention or obligation
to update any forward-looking statements.
Source: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Kelly Luethje, 617-679-5519
kluethje@iderapharma.com
or
MacDougall
Biomedical Communications
Chris Erdman, 781-235-3060
cerdman@macbiocom.com
